Investor Relations, Public Relations and Marketing Services for Life Sciences Companies. Founded by industry vets Daniel Eramian and Charles S. Craig

Seattle, Atlanta, Los Angeles, USA
Joined October 2008
Opus Biotech Comm retweeted
@DiakonosOnc to present poster at #AACR24 on Dendritic Cell Vaccine #immunotherapy for #GBM. Therapies have generated encouraging efficacy and safety in clinical trials to date. Company leadership will be available for meetings. @AACR #cancerresearch #cancer #biopharma
2
1
107
Great news for @NSTherapeutics team. This @NatEyeInstitute @NIH grant will advance our #genetherapy for Age-Related Macular Degeneration #AMD #opthalomology #retina bit.ly/3AplXid
1
4
Great news in the fight against #HIV #AIDS @hdtbio @NIH @NIAIDFunding #vaccines
Replying to @hdtbio
@hdtbio excited to move toward a vaccine for #HIV-1 with a 3-year grant from @NIH #NIAID. Congrats @KhandharAmit Dir. of Formulation, the PI on this award, and to our LION team for all their hard work. #aids #publichealth #VaccinesWork bit.ly/3eQUFsC
1
Exciting developments to ultimate make #CovidVaccine available to more people.
Replying to @hdtbio
@hdtbio is featured in @ScienceMagazine on the challenge of making #COVID19 vaccines with less refrigeration requirements to better serve populations across the globe where refrigeration is in short supply. #COVID19 #covid19vaccine #mrnavaccines bit.ly/2RLvhLB
Outstanding additions to this company that is doing great things!
Replying to @NSTherapeutics
@NSTherapeutics announces new clinical advisory board including Michael Singer, MD; Stephen H. Tsang, MD, PhD; Paul Yang, MD, PhD; and Srinivas R Sadda. #retinitispigmentosa #stargardsdisease #AMD #genetherapy #rarediseases #optogenetics bit.ly/2RE9eGC
Great new technology from @hdtbio in this interesting article.
MIT @techreview recently featured @hdtbio CSO Darrick Carter on how HDT's #mRNA #Covid-19 technology can overcome the storage and distribution challenges of current vaccines in use which limit access in developing nations. Read it here: bit.ly/2PIdDrB #VACCINES
Exciting new research! #photonicswest
Replying to @NSTherapeutics
@NSTherapeutics is at @PhotonicsWest with multiple presentations featuring groundbreaking research in optical gene delivery and opsin-based neuromodulation therapy. @SPIEtweets for details: #https://prn.to/3rnttp3 #optogenetics #genetherapy
1
Opus Biotech Comm retweeted
@hdtbio announces additional $3M as part of seed financing round led by @ZoicCapital for a total raise of $6M. Funds support advancing 3 lead products into clinical trials this year. Details: bit.ly/3u22YqZ #immunotherapy #oncology #vaccines #biotech
2
2
@Opus_Biotech is pleased to partner with @CxPrecisionM, a biotech company developing blood-based diagnostics for early assessment and treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. cxprecisionm.com #Alzheimers #Parkinsons
1
1
1
Really exciting news about a promising treatment for #pancreaticcancer #pancan #cancertreatment #clinicaltrials
Replying to @nanology
@Nanology announces first patient enrolled in expansion of #pancreaticcancer #clinicaltrial. More Details: bit.ly/3ihLXD3
Great news from @NanOlogyLLC about their #bladder cancer program. Check nanology.us for info about programs for #lung cancer #prostatecancer #pancreaticcancer and more. Very interesting and promising.
Replying to @NanOlogyLLC
@NanOlogyLLC Bladder Cancer Trial Enrollment Progress! We are very excited by the therapeutic potential of NanoDoce in #bladdercancer. Read more: bit.ly/3jhQ1De #cancer #clinicaltrial #CancerResearch
Opus Biotech Comm retweeted
@NanOlogyLLC to SF for #JPM2020. Now setting mtgs w/potential partners & investors to discuss clinical progress of our therapeutic drug platform in gastrointestinal, genitourinary, peritoneal, lung & other cancers. Contact [email protected] nanology.us #pancan
1
1
Go Heather Giles!
Vapogenix attended the Texas Life Science Forum 2019. Wonderful event! Kudos to the organizers. #TLSF2019 @BioHouston @ricealliance
Exciting news for patients
Today announced results of Phase II trial of our lead product, VPX638, a topical non-opioid, lidocaine-free analgesic. Data reveals VPX638 significantly reduces pain and use of opioids. Read more: bwnews.pr/2NgzHUM #opioidcrisis #painrelief #painmanagement
Great opportunity to hear from Houston-based @Vapogenix
Vapogenix is presenting at the Texas Life Science Forum in Houston on Wednesday November 6th, 2019 "Uncovering Strategies for Planning and Executing a Clinical Trial in Australia" #TXLSF #Pain #Australiaclinicaltrials
Great tip for anyone in Toronto tomorrow!
Replying to @theaaih
@theaaih President & Co-Founder Annastasiah Mudiwa Mhaka, PhD in Toronto tomorrow 4/3 for @MaRS Healthkick Invest, part of #HIW2019. Catch up with her on 4/3 at the panel on #AI and #BigData: Therapeutics. buff.ly/2I0AtV0
Really like this guy!
Tonight @txhbi honors @MDAndersonNews professor and Nobel Prize Winner Jim Allison, PhD #THBISummit2019
1